Mabwell(SH:688062) Zheng Quan Zhi Xing·2025-08-05 16:20Core Viewpoint - The company, Maiwei (Shanghai) Biotechnology Co., Ltd., has announced an adjustment to the upper limit of its share repurchase price from RMB 35.00 per share to RMB 48.00 per share to ensure the smooth implementation of its share repurchase plan [1][2][7] Summary of Share Repurchase Plan - The company plans to repurchase its issued A-shares through centralized bidding on the Shanghai Stock Exchange, with a total repurchase fund not less than RMB 25 million and not exceeding RMB 50 million [1][6] - The repurchase period is set for 12 months from the date of the board's approval of the repurchase plan [1] Reasons for Adjustment - The adjustment to the repurchase price limit is due to the recent continuous rise in the company's stock price, reflecting confidence in the company's future stable development and recognition of its value [2][5] - The new upper limit of RMB 48.00 per share is based on the company's comprehensive consideration of market conditions and the progress of the share repurchase [6][7] Company’s Product Pipeline - The company has a robust pipeline with 16 core products in various stages, including 12 innovative drugs and 4 biosimilars, with 4 already on the market [2][3] - Notable products include 9MW2821, which has received multiple designations from the FDA, and other innovative monoclonal antibodies with significant potential in treating various diseases [3][4] Financial Performance - The company reported a sales revenue of RMB 139 million for its product Deshu Single Antibody in 2024, marking a year-on-year increase of 230.17% [4] - The company has signed licensing agreements with other pharmaceutical companies, which include substantial upfront payments and potential royalties based on sales [5] Decision-Making Process - The adjustment to the repurchase price limit was approved in a board meeting held on August 5, 2025, and does not require shareholder approval [7]